Trodelvy: First-Line TNBC Hope
EU Commission Authorizes Gilead's Trodelvy as First-Line Therapy for Metastatic TNBC
Key Points
The ASCENT-03 trial used a crossover design that allowed patients in the chemotherapy arm to switch to Trodelvy upon progression, which can influence overall survival analyses even as progression-free survival showed a benefit.
Trodelvy is an antibody-drug conjugate targeting Trop-2 on cancer cells and delivering a chemotherapy payload, a mechanism that differentiates it from traditional cytotoxic regimens in TNBC.
EU access is expanding beyond the 27 EU member states to include Norway, Iceland and Liechtenstein, broadening first-line metastatic TNBC treatment options in the European Economic Area region.
Dr. Javier Cortes, head of the International Breast Cancer Center, called the approval a profound sense of hope for metastatic TNBC patients, underscoring the urgent need for progress in this disease area.
The European Commission has approved Trodelvy (sacituzumab govitecan-hziy) as a first-line treatment for metastatic triple-negative breast cancer, making it the first antibody-drug conjugate to reach this setting in Europe. The decision, announced June 23, 2026, covers adult patients who cannot receive immune checkpoint inhibitors — a group with almost no good options until now, according to Business Wire.
Triple-negative breast cancer is the most aggressive breast cancer subtype. It accounts for about 15% of all breast cancers and carries a five-year survival rate of just 12% in the metastatic setting, compared to 28% for other metastatic breast cancers, according to Investing.com. Almost half of patients never make it to a second line of treatment.
ASCENT-03 Trial Data That Drove the Decision
The approval rests on results from the Phase 3 ASCENT-03 trial. Trodelvy cut the risk of disease progression or death by 38% compared to standard chemotherapy, according to OncLive. Median progression-free survival was 9.7 months on Trodelvy versus 6.9 months on chemo — a gap that regulators deemed highly statistically significant and clinically meaningful.
One design detail drew scrutiny. Patients in the chemotherapy arm could switch to Trodelvy after their cancer progressed — a common ethical practice. Critics note this crossover can blur overall survival results, making it harder to prove a definitive survival benefit beyond the clear PFS gain, according to StreetInsider.
How Trodelvy Works Differently From Standard Chemo
Trodelvy is an antibody-drug conjugate, or ADC. That means it is a targeted drug with two parts: an antibody that seeks out a protein called Trop-2 on cancer cells, and a chemotherapy payload called SN-38 that it delivers directly to the tumor. This approach aims to kill cancer cells while reducing the wider toxic effects of traditional chemotherapy, according to Pharmacy Times.
The drug does carry serious risks. Its label includes a boxed warning — the FDA's strongest caution — for severe neutropenia, a dangerous drop in white blood cells, and severe diarrhea. Experts say managing these side effects requires more intensive monitoring than standard chemo regimens, according to StreetInsider.
Doctors and Advocates Call It a 20-Year Breakthrough
Dr. Javier Cortes, head of the International Breast Cancer Center and the ASCENT-03 principal investigator, said the approval gives patients a "profound sense of hope." He added: "For women diagnosed with metastatic TNBC, particularly those who are younger, every second counts." His remarks were carried in the Gilead Sciences press release.
TNBC disproportionately affects younger, premenopausal, Black, and Hispanic women. The EU approval extends to the full European Economic Area — 27 EU member states plus Norway, Iceland, and Liechtenstein — broadening access to roughly 450 million people, according to Business Wire.
Gilead's Next Moves and Growing Competition
Gilead is not stopping here. The company has filed in Europe to add Trodelvy in combination with Keytruda (pembrolizumab) for patients whose tumors test positive for PD-L1. That combination cut the risk of progression by 35% in the ASCENT-04 trial, with median PFS of 11.2 months versus 7.8 months on chemo plus Keytruda, according to Merck. The EMA is currently reviewing the filing.
Trodelvy is already a financial cornerstone for Gilead. Sales surged 37% year-over-year to reach $1.4 billion in 2025, and the company posted $7.0 billion in total Q1 2026 revenue, according to Nasdaq. But competition is building. AstraZeneca and Daiichi Sankyo's Datroway recently won FDA approval for a similar patient population, signaling that the first-line TNBC space is becoming a battleground for next-generation ADCs, according to FirstWord Pharma.
Sentiment
Mostly PositivePublishers
12
Articles
32
Reach
44
